0.00Open0.00Pre Close0 Volume0 Open Interest320.00Strike Price0.00Turnover51.66%IV-26.45%PremiumDec 20, 2024Expiry Date66.93Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9888Delta0.0032Gamma3.78Leverage Ratio-0.0118Theta-0.0253Rho-3.74Eff Leverage0.0151Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet